Telbivudine

Drug Profile

Telbivudine

Alternative Names: 2'-deoxy-L-thymidine; Epavudine; L-dT; LDT-600; NV-02B; Sebivo; Tyzeka

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Centre National de la Recherche Scientifique; Idenix Pharmaceuticals; University of Montpellier II
  • Developer Novartis
  • Class Antivirals; Nucleosides; Pyrimidines; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis B

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 16 Jun 2015 Launched for Hepatitis B in Croatia, Finland, Georgia, Latvia, Lithuania, Romania, Oman, Serbia, Armenia, Singapore, Slovakia, Slovenia, South Africa, Taiwan, Venezuela, Estonia, Malta, Hungary, Bahrain, Saudi Arabia, Qatar, Jordan, Nigeria, Sri Lanka, India and Bangladesh (PO) before June 2015
  • 01 Oct 2014 Phase-III clinical trials in Hepatitis B (In adolescents) in Greece, Turkey and the United Kingdom (PO, tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top